LPCN

Lipocine Inc. (LPCN) Risks & Opportunities Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Financial Strength

Very strong liquidity with a current ratio of 11.48x and cash ratio of 2.41x.

No debt on the balance sheet, keeping leverage risk low.

Working capital remains positive at $21.7M, supporting near-term flexibility.

Profitability

TTM margins remain deeply negative, with operating margin at -8.01% and net margin at -7.55%.

Returns are still poor, with ROA at -49.7%, ROE at -64.7%, and ROIC at -57.7%.

Gross margin is extremely high at 98.1%, but it is not translating into bottom-line profitability.

Valuation

The stock screens as asset-backed, with price-to-book at 0.92x and price-to-fair-value at 0.92x.

Price-to-sales remains elevated at 12.82x despite weak profitability.

Negative earnings and cash flow make earnings-based valuation metrics less reliable.

Cash Flow

TTM operating cash flow and free cash flow are both negative, with FCF yield at -55.6%.

Free cash flow to equity is negative at -$11.2M, indicating ongoing cash burn.

Cash conversion cycle is highly negative due to very large payables outstanding, but this does not offset the weak cash generation.

Operational Efficiency

Asset turnover is low at 0.066x, reflecting limited revenue generation from the asset base.

Receivables turnover is modest at 5.39x, while days sales outstanding is 67.7 days.

The business shows strong fixed-asset turnover, but overall operating efficiency remains constrained by losses.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Lipocine Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →